CD33 and acute myeloid leukemia: Several AML studies have applied this strategy, with CARs targeting antigens like CD123, CD33, and CLL-1, and iCARs inhibiting T cell activity when binding to endothelial antigens like CD93 [170], or myeloid lineage antigens like CD15 and CD16 [171], or CD16b and CLEC9A [172] (Table 3).